Top in endocrinology: Antidepressants and diabetes risk, resveratrol

A recent study demonstrated an elevated risk for type 2 diabetes among women receiving antidepressant medication compared with nonusers. It was the top story in endocrinology last week.

Another top story is about new data that suggest resveratrol may help prevent bone loss in postmenopausal women without osteoporosis.

Read these and more top stories in endocrinology below:

Antidepressants elevate risk for type 2 diabetes

A cohort of French women currently taking any antidepressant medication were more likely to develop type 2 diabetes during 6 years of follow-up compared with nonusers, independent of severe depressive symptoms. Read more.

Resveratrol boosts bone density for postmenopausal women

A naturally occurring polyphenol in red grapes and berries may provide a prophylactic benefit for preventing bone loss in postmenopausal women without osteoporosis, according to data published in the Journal of Bone and Mineral Research. Read more.

Mild thyroid dysfunction at birth does not predict mid-childhood IQ

Children with mildly elevated thyroid-stimulating hormone levels at birth have normal thyroid function in mid-childhood and have neurocognitive abilities similar to their sibling controls, study data show. Read more.

European protocol shows pilots with insulin-treated diabetes can safely fly

Pilots with insulin-treated diabetes who followed a strict European safety protocol maintained glucose levels in a safe range for 98% of flight time during 4 years of follow-up, with no episodes of pilot incapacitation, study data show. Read more.

UnitedHealthcare to cover Tandem insulin pumps in network

UnitedHealthcare will now cover Tandem Diabetes’ insulin pumps in network, a reversal of a previous policy that limited pump choices for adults and children with diabetes. Read more.